Simulations Plus (SLP) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Total funding raised: $30.5M

Market Cap: $322.0MFounded: 1996HQ: Lancaster, United States

Sector Ranking#27 in AI / Machine Learning #60 in Digital Health & Biotech SaaS

Overview

Simulations Plus is a mission-driven company focused on improving human health by translating rigorous science into trusted software and expert consulting services. Over nearly three decades, it has established itself as a dominant force in the biosimulation market, with a hybrid software-and-services model that generates recurring revenue from over 280 clients. Its strategy centers on integrating AI/ML across its flagship platforms—GastroPlus, ADMET Predictor, MonolixSuite, DILIsym, and Thales—to enhance predictive accuracy and workflow efficiency, thereby capitalizing on the industry's shift towards MIDD to reduce R&D costs and accelerate timelines.

AI / Machine Learning

Technology Platform

A portfolio of integrated AI/ML-powered biosimulation software platforms, including GastroPlus (PBPK/PBBM), ADMET Predictor (AI-driven drug design), MonolixSuite (pharmacometrics), DILIsym (QST for liver safety), and Thales (QSP), supporting drug development from discovery through commercialization.

Funding History

4

Total raised:$30.5M

PIPE$25MUndisclosedDec 15, 2020

Debt$5MUndisclosedJun 15, 2012

Grant$500KNational Institutes of HealthJun 15, 2005

IPOUndisclosedUndisclosedJun 15, 1997

Opportunities

The company is poised to capitalize on the strong secular trend towards Model-Informed Drug Development (MIDD), driven by regulatory endorsement and the biopharma industry's need to reduce R&D costs and failure rates.

Growth opportunities include expanding SaaS subscriptions, cross-selling its full software suite (especially QSP and QST platforms) into its large client base, and leveraging AI integration to create next-generation workflows.

Risk Factors

Key risks include reliance on large pharmaceutical clients, intense competition from both specialized and diversified software firms, the need for continuous high-level innovation in AI/ML, and potential challenges in integrating acquired technologies.

Macroeconomic pressures could also temporarily impact discretionary consulting spend.

Competitive Landscape

Simulations Plus competes directly with biosimulation leader Certara, as well as other players like Schrödinger (AI-driven discovery) and Dassault Systèmes. Its primary advantages are its fully integrated software portfolio spanning the entire drug development lifecycle, deep scientific validation, a hybrid software-and-consulting model, and entrenched relationships with the vast majority of top global pharma companies.